Jian Xiao Selected Research

3-n-butylphthalide (butylphthalide)

3/2021	DL-3-n-butylphthalide ameliorates diabetes-associated cognitive decline by enhancing PI3K/Akt signaling and suppressing oxidative stress.
1/2021	Dl-3-n-Butylphthalide Ameliorates Diabetic Nephropathy by Ameliorating Excessive Fibrosis and Podocyte Apoptosis.
11/2017	Dl-3-n-butylphthalide attenuates acute inflammatory activation in rats with spinal cord injury by inhibiting microglial TLR4/NF-κB signalling.
1/2017	Dl-3-n-butylphthalide prevents the disruption of blood-spinal cord barrier via inhibiting endoplasmic reticulum stress following spinal cord injury.
1/2017	Dl-3-n-butylphthalide improves functional recovery in rats with spinal cord injury by inhibiting endoplasmic reticulum stress-induced apoptosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jian Xiao Research Topics

Disease

78	Neoplasms (Cancer) 01/2022 - 05/2007
46	Spinal Cord Injuries (Spinal Cord Injury) 10/2022 - 01/2013
33	Inflammation (Inflammations) 10/2022 - 03/2010
28	Wounds and Injuries (Trauma) 01/2022 - 01/2008
22	Hypoxia (Hypoxemia) 01/2022 - 12/2008
20	Stomach Neoplasms (Stomach Cancer) 05/2022 - 11/2014
14	Ischemia 10/2021 - 03/2007
13	Pain (Aches) 02/2022 - 11/2018
13	Brain Injuries (Brain Injury) 10/2019 - 12/2009
12	Adenocarcinoma of Lung 01/2022 - 10/2014
11	Neoplasm Metastasis (Metastasis) 01/2022 - 07/2015
11	Fibrosis (Cirrhosis) 01/2021 - 11/2013
10	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2022 - 12/2016
9	Glioma (Gliomas) 09/2021 - 02/2016
9	Rectal Neoplasms (Rectal Cancer) 12/2019 - 10/2012
8	Carcinogenesis 01/2022 - 12/2015
8	Myocardial Infarction 07/2021 - 03/2011
8	Infections 10/2020 - 04/2014
7	Chronic Obstructive Pulmonary Disease (COPD) 09/2021 - 01/2016
6	Reperfusion Injury 01/2022 - 07/2010
6	Peripheral Nerve Injuries 01/2022 - 02/2017
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2021 - 09/2012
6	Cicatrix (Scar) 01/2021 - 01/2013
6	Myocardial Ischemia (Ischemic Heart Diseases) 01/2021 - 12/2008
6	Brain Ischemia (Cerebral Ischemia) 12/2019 - 12/2009
6	Pressure Ulcer (Bedsore) 12/2015 - 07/2012
5	Colorectal Neoplasms (Colorectal Cancer) 12/2021 - 11/2009
5	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2021 - 10/2014
5	Carcinoma (Carcinomatosis) 01/2021 - 05/2007
5	Nasopharyngeal Carcinoma 10/2020 - 04/2010
5	Lung Neoplasms (Lung Cancer) 04/2020 - 06/2011
5	Epilepsy (Aura) 01/2020 - 01/2016
5	Gliosis 01/2020 - 12/2015
5	Atrial Fibrillation 01/2020 - 01/2018
4	Osteoarthritis 01/2022 - 01/2018
4	Cognitive Dysfunction 01/2022 - 12/2016
4	Necrosis 01/2022 - 01/2016
4	Pancreatitis 01/2022 - 01/2018
4	Hyperalgesia 07/2021 - 11/2018
4	Hyperglycemia 01/2021 - 01/2017
4	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2015
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 10/2016
4	Type 2 Diabetes Mellitus (MODY) 01/2021 - 11/2016
4	Mitochondrial Diseases (Mitochondrial Disease) 01/2020 - 03/2015
4	Crush Injuries 01/2020 - 02/2017

Drug/Important Bio-Agent (IBA)

41	Proteins (Proteins, Gene)FDA Link 05/2022 - 12/2009
24	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 01/2021 - 12/2009
23	Pharmaceutical PreparationsIBA 01/2022 - 07/2010
19	HydrogelsIBA 01/2022 - 01/2016
18	Neuroprotective AgentsIBA 01/2022 - 12/2009
14	Biomarkers (Surrogate Marker)IBA 03/2021 - 08/2016
14	Fibroblast Growth Factor 1 (FGF-1)IBA 01/2021 - 03/2007
13	CollagenIBA 01/2022 - 10/2012
12	Nerve Growth Factor (NGF)IBA 11/2021 - 05/2014
12	Heparin (Liquaemin)FDA LinkGeneric 01/2021 - 01/2016
11	Therapeutic UsesIBA 01/2021 - 07/2011
10	Messenger RNA (mRNA)IBA 01/2020 - 05/2007
10	CurcuminIBA 10/2017 - 03/2009
9	Biological ProductsIBA 01/2022 - 09/2006
8	Poloxamer (Poloxamer 407)IBA 01/2022 - 01/2016
8	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 01/2021 - 10/2014
8	fibroblast growth factor 21IBA 11/2019 - 12/2010
7	EnzymesIBA 01/2022 - 03/2007
7	Opioid Analgesics (Opioids)IBA 07/2021 - 02/2016
7	LipidsIBA 01/2021 - 04/2010
7	CytokinesIBA 01/2021 - 01/2015
7	Liposomes (Liposome)IBA 07/2020 - 01/2012
6	Small Interfering RNA (siRNA)IBA 01/2022 - 03/2014
6	InflammasomesIBA 01/2022 - 10/2019
6	Analgesics (Analgesic Drugs)IBA 01/2022 - 11/2018
6	Oxygen (Dioxygen)IBA 08/2021 - 12/2009
6	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2021 - 01/2015
6	MicroRNAs (MicroRNA)IBA 01/2021 - 03/2011
6	isoliquiritigenin (GU 17)IBA 02/2019 - 01/2018
5	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 04/2022 - 01/2010
5	Long Noncoding RNAIBA 01/2022 - 04/2019
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 01/2012
5	3-n-butylphthalide (butylphthalide)IBA 03/2021 - 01/2017
5	AntioxidantsIBA 01/2021 - 03/2010
5	SolutionsIBA 10/2020 - 11/2016
5	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 02/2014
4	Formaldehyde (Formol)FDA Link 02/2022 - 12/2018
4	CreatinineIBA 01/2022 - 04/2011
4	NitrogenIBA 01/2022 - 04/2011
4	LipopolysaccharidesIBA 09/2021 - 01/2016
4	SmokeIBA 09/2021 - 10/2017
4	ErbB Receptors (EGF Receptor)IBA 04/2021 - 01/2020
4	Tretinoin (Retinoic Acid)FDA LinkGeneric 02/2021 - 01/2016
4	CateninsIBA 01/2021 - 01/2016
4	Peptides (Polypeptides)IBA 10/2020 - 05/2010
4	phenylalanyl- leucyl- phenylalanyl- glutaminyl- prolyl- glutaminyl- arginyl- phenylalaninamideIBA 08/2020 - 12/2018
4	CarrageenanIBA 03/2020 - 09/2013

Therapy/Procedure

45	Therapeutics 01/2022 - 01/2010
13	Drug Therapy (Chemotherapy) 01/2022 - 11/2009
11	Neoadjuvant Therapy 12/2021 - 10/2012
6	Radiotherapy 01/2021 - 08/2016
6	Aftercare (After-Treatment) 04/2020 - 03/2011
5	Transplantation 08/2021 - 01/2016
4	Injections 10/2021 - 11/2016
4	Analgesia 04/2020 - 12/2018